Thursday, November 19, 2009

AstraZeneca Submits US New Drug Application for Ticagrelor (Brilinta), an Investigational Antiplatelet Agent

AstraZeneca today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ticagrelor, an investigational oral antiplatelet treatment for the reduction of major adverse cardiac events in patients with acute coronary syndrome (ACS).

The details can be read here.

No comments: